Replimune Group (NASDAQ:REPL) Releases Earnings Results, Misses Expectations By $0.09 EPS

Replimune Group (NASDAQ:REPL) announced its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09), Zacks reports.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded up $0.53 during mid-day trading on Wednesday, hitting $13.38. 327,286 shares of the company were exchanged, compared to its average volume of 764,142. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $12.49 and a 200-day simple moving average of $11.64. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a market cap of $915.46 million, a price-to-earnings ratio of -4.39 and a beta of 1.30.

Wall Street Analyst Weigh In

REPL has been the subject of a number of analyst reports. Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets increased their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright raised their target price on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $19.14.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.